# Study of the Safety and Efficacy of MK-4827 Given With Temozolomide in Participants With Advanced Cancer (MK-4827-014 AM1)

> **NCT01294735** · PHASE1 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 19 (actual)

## Conditions studied

- Recurrence of Solid Tumor
- Glioblastoma Multiforme
- Melanoma

## Interventions

- **DRUG:** MK-4827
- **DRUG:** Temozolomide

## Key facts

- **NCT ID:** NCT01294735
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-02
- **Primary completion:** 2012-04
- **Final completion:** 2012-05
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2012-08-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01294735

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01294735, "Study of the Safety and Efficacy of MK-4827 Given With Temozolomide in Participants With Advanced Cancer (MK-4827-014 AM1)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01294735. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*